| 190 | 17 | 8 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探讨重组人血管内皮抑制素对非小细胞肺癌患者治疗效果、血管新生、肿瘤细胞增殖及迁移的影响。方法:选择我院收治的100例非小细胞肺癌患者作为研究对象,随机分为观察组与对照组,每组各50例。对照组采用吉西他滨联合顺铂治疗;观察组在对照组基础上联合恩度治疗。观察比较两组癌症治疗效果[包括细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原(CA50)]、血管新生[包括血管内皮生长因子(VEGF)及低氧诱导因子(HIF-1α)]、肿瘤细胞增殖[包括胰岛素样生长因子(IGF-1)、胰岛素样生长因子受体-7(IGFBP-7)]及迁移[包括高迁移率族蛋白AT-hook2(HMGA2)、高迁移率族蛋白B1(HMGB1)]相关指标的表达水平。结果:两组研究对象在治疗效果、血管新生、肿瘤细胞增殖及迁移方面变化明显。治疗前,两组各项水平比较,无显著差异(P>0.05);治疗后,两组CY-FRA21-1、CEA、CA50、VEGF、HIF-1α、IGF-1、HMGA2及HMGB1水平均较治疗前显著降低(P<0.05),IGFBP-7水平则较治疗前显著升高(P <0.05);且治疗后观察组CYFRA21-1、CEA、CA50、VEGF、HIF-1α、IGF-1、HMGA2及HMGB1水平较对照组下降明显(P<0.05),IGFBP-7水平则较对照组升高明显(P<0.05)。结论:重组人血管内皮抑制素可增强对非小细胞肺癌患者的治疗效果,减少血管新生,抑制肿瘤细胞增殖及迁移。
Abstract：Objective:To investigate the effects of recombinant human endostatin on therapeutic effect,angiogenesis,tumor cell proliferation and migration in patients with non-small cell lung cancer.Methods:100 patients with non-small cell lung cancer treated in our hospital from September 2015 to March 2018 were selected as research subjects.They were randomly divided into observation group and control group,50 cases in each group.The control group was treated with gemcitabine plus cisplatin,while the observation group was combined with Endostar treatment on the basis of the control group.Observed and compared the expression of the therapeutic effect[including cytokeratin 19 fragment (CYFRA21-1),carcinoembryonic antigen (CEA)and carbohydrate antigen (CA50)],angiogenesis[including vascular endothelial growth factor (VEGF)and hypoxia inducible factor (HIF-1 alpha)],tumor cell proliferation[including insulin-like growth factor (IGF-1)and insulin-like growth factor receptor-7 (IGFBP-7)]and migration[including high mobility group protein AT-hook2 (HMGA2)and high mobility group protein B1 (HMGB1)]in two groups.Results:The two groups showed significant changes in the therapeutic effect,angiogenesis,proliferation and migration of tumor cells.Before treatment,there was no significant difference in all levels between the two groups (P>0.05).After treatment,the levels of CYFRA21-1,CEA,CA50,VEGF,HIF-1 a,IGF-1,HMGA2 and HMGB1 in the two groups were significantly lower than those before treatment (P<0.05),while the levels of IGFBP-7 were significantly higher than those before treatment (P<0.05).After treatment,the levels of CYFRA21-1,CEA,CA50,VEGF,HIF-1 a,IGF-1,HMGA2 and HMGB1 in the observation group were significantly lower than those in the control group (P<0.05),while the levels of IGFBP-7 were significantly higher than those in the control group (P<0.05).Conclusions:Recombinant human endostatin can enhance the therapeutic effect of non-small cell lung cancer patients,reduce angiogenesis,inhibit tumor cell proliferation and migration
1陈洁,苟淑萍,栾文革.重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及对VEGF、HIF-1α、肿瘤标志物的影响[J].临床和实验医学杂志,2014,13(21):1778-1780.
2凌华晃,黄锡梅,李涛,等.恩度联合化疗治疗中晚期非小细胞肺癌的疗效及相关因素分析[J].中国肿瘤临床与康复,2015,22(3):295-297.
3 Wang J,Wang K,Xu J,et al.Correction:Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients:A meta-analysis[J].Plos One,2013,8(11):e78070.
4 Rossi A,Chiodini P,Sun JM,et al.Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer:A systematic review and meta-analysis of individual patient data[J].Lancet Oncology,2014,15(11):1254-1262.
5宋勇,杨雯.2014年晚期非小细胞肺癌内科治疗进展[J].解放军医学杂志,2015,40(1):10-15.
6张金忠,牟坤,王继松.紫杉醇、顺铂联合重组人血管内皮抑制素对非小细胞肺癌患者的疗效及相关指标的影响[J].中国药房,2016,27(30):4218-4220.
7王越希,陈晓梅,晏军,等.重组人血管内皮抑制素联合顺铂化疗方案对中晚期非小细胞肺癌患者外周血sPD-L1、CEA水平的影响[J].疑难病杂志,2016,15(5):476-478.
8贾桂英.重组人血管内皮抑制素联合VP方案对晚期非小细胞肺癌患者外周血肿瘤标志物水平的影响[J].中国实用医刊,2017,44(16):25-27.
9韩敏,王坚,王久胜.重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清LMTK-3、IGFBP-7的影响[J].中国现代医学杂志,2018,28(9):55-59.
10王强,马玲,陶洁,等.恩度联合化疗对晚期非小细胞肺癌患者血清EPO、EPO-R mRNA水平的影响[J].山东医药,2017,57(6):38-40.
11赵柏林,戈伟,郑永法,等.恩度联合同步放化疗治疗局部晚期非小细胞肺癌的临床效果[J].中国医药导报,2016,(14):84-87.
12石远凯,孙燕,于金明,等.中国晚期原发性肺癌诊治专家共识(2016年版)[J].中国肺癌杂志,2016,19(1):1-15.
13谢亚琳,梁继珍,苏宁.吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较[J].南方医科大学学报,2015,35(3):446-449.
14朱志真,石建华,侯森.恩度联合顺铂局部治疗非小细胞肺癌合并恶性胸腔积液的疗效及对VEGF、HIF-1α的影响[J].实用癌症杂志,2014,29(7):855-857.
15 Wong W,Sun P,Mu Z,et al.Efficacy and safety of nab-paclitaxel as second-line chemotherapy for locally advanced and metastatic non-small cell lung cancer[J].Anticancer Research,2017,37(8):4687-4691.
16 Otsuka T,Nojiri T,Minami S,et al.Evaluation of natriuretic peptide in non-small cell lung cancer patients treated with bevacizumab together with carboplatin-paclitaxel:A prospective study[J].Anticancer Research,2017,37(7):3505-3512.
17 Zhang L,Liu D,Li L,et al.The important role of circulating CYFRA21-1in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients[J].Bmc Cancer,2017,17(1):96.
18 Shintani T,Matsuo Y,Iizuka Y,et al.Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy[J].Anticancer Research,2017,37(9):5161-5167.
19 Frezzetti D,Gallo M,Maiello MR,et al.VEGF as a potential target in lung cancer[J].Expert Opinion on Therapeutic Targets,2017,21(10):959-966.
20 Pastuszaklewandoska D,Kordiak J,Czarnecka KH,et al.Expression analysis of three miRNAs,miR-26a,miR-29band miR-519d,in relation to MMP-2expression level in non-small cell lung cancer patients:apilot study[J].Medical Oncology,2016,33(8):96.
21吴新天,周韶璋,莫娟梅,等.HIF-1α、VEGF和TGF-β1在非小细胞肺癌中的表达及其临床意义[J].中国癌症防治杂志,2013,5(1):46-49.
22 Tsuchida R,Osawa T,Wang F,et al.BMP4/Thrombospondin-1loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors[J].Oncogene,2013,33(29):3803-3811.
23 Wang YY,Ren T,Cai YY,et al.MicroRNA let-7ainhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95Dby regulating K-Ras and HM-GA2gene expression[J].Cancer Biotherapy&Radiopharmaceuticals,2013,28(2):131-137.
24 Lu B,Antoine DJ,Kwan K,et al.JAK/STAT1signaling promotes HMGB1 hyperacetylation and nuclear translocation[J].Proceedings of the National Academy of Sciences of the United States of America,2014,111(8):3068-3073.
25 Feng A,Tu Z,Yin B.The effect of HMGB1on the clinicopathological and prognostic features of non-small cell lung cancer[J].Oncotarget,2016,7(15):20507-20519.
26臧晔.恩度联合TP方案化疗同步放疗对非小细胞肺癌患者血清中HMGA2、HMGB1的影响[J].现代肿瘤医学,2017,25(24):3997-4000.
基本信息:
DOI：10.13210/j.cnki.jhmu.20181219.001
中图分类号:R734.2
引用信息:
[1]凌敏文,王洁,丁红梓.重组人血管内皮抑制素对非小细胞肺癌患者治疗效果、血管新生、肿瘤细胞增殖及迁移的影响[J].海南医学院学报,2019,25(02):133-136+140.DOI:10.13210/j.cnki.jhmu.20181219.001.
基金信息:
南京市医学科技发展项目(YKK16207)~~
2018-12-21
2018-12-21
2018-12-21